Search
Cupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: ADDAMEL N, ADDAMEL NPaspalum notatum pollen
go.drugbank.com/drugs/DB10349ApprovedPaspalum notatum pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS336682, Treatment Set TS339754Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Prothrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Acer saccharinum pollen
go.drugbank.com/drugs/DB10735ApprovedAcer saccharinum pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872Nafarelin
go.drugbank.com/drugs/DB00666ApprovedInvestigationalNafarelin has been used in the treatments of central precocious puberty and endometriosis. … Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6.
Products: Synarel Nas Sol 2mg/mlFlavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
Mixtures: EnlIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Elymus repens pollen
go.drugbank.com/drugs/DB10489ApprovedElymus repens pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872